Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease

NCT: NCT07764146 · NOT_YET_RECRUITING

NCT IDNCT07764146
StatusNOT_YET_RECRUITING
Start Date2026-08-24
Completion2029-04-28
SponsorVoyager Therapeutics (INDUSTRY)
First posted
Last updated

Brief Summary

VY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study

Frequently Asked Questions

What is An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease?

An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease is a clinical trial registered under NCT07764146. Current status: NOT_YET_RECRUITING.

What is the status of NCT07764146?

The current status of NCT07764146 (An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease) is: NOT_YET_RECRUITING.

When did An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease start?

An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease started on 2026-08-24.

Related Devices

K180854Voyager Trajectory Array Guide (V-TAG)Voyager Therapeutics, Inc.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑